A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma	Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 2	2026-09-04		NCT07637578

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Pfizer	431
SCRI Development Innovations, LLC	7

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Colorado Blood Cancer Institute	Denver	United States	178
Comprehensive Cancer Centers of Nevada	Las Vegas	United States	34
Maryland Oncology Hematology	Columbia	United States	6
Rocky Mountain Cancer Center	Denver	United States	13
Scri Oncology Partners	Nashville	United States	156
Willamette Valley Cancer Institute and Research Center	Eugene	United States	17